GlassScriptPhysician profile
Thomas O Perkins
NPI 1821026212
$2,744.83
in general payments reported to CMS, 2019-2025
20 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $693 · 2022: $714 · 2023: $794 · 2024: $381 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318 · Education: $19.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.73 |
| Education | $19.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $829.18 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $378.61 | 2021-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $351.02 | 2021-2024 | Belsomra, Steglatro, Steglujan |
| Amarin Pharma, INC. | $317.54 | 2021-2022 | |
| Glaxosmithkline, LLC. | $162.60 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $144.04 | 2021-2024 | |
| Dexcom, INC. | $98.68 | 2021-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $92.57 | 2021-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $66.52 | 2021-2023 | |
| Abbott Laboratories | $52.68 | 2021-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $39.76 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.49 | 2023 | Trintellix |
| Amgen INC. | $29.25 | 2021-2022 | |
| Exact Sciences Corporation | $26.44 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $26.16 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $24.56 | 2021 | |
| Horizon Therapeutics Plc | $17.90 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.94 | 2022 | |
| Allergan, INC. | $16.87 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.02 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.